# OnCo record nct06534437 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06534437/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06534437", "NCT06534437" ;
  schema:name "MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)"@en ;
  schema:alternateName "JASPIS-01"@en ;
  schema:description "A phase 2 trial of MEN1703, Glofitamab in hodgkin lymphoma and non-hodgkin lymphoma, run by Ryvu Therapeutics SA, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06534437/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06534437> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-12-05" ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/men1703/>, <https://onco.cc/drugs/glofitamab/> ;
  onco:companies <https://onco.cc/companies/ryvu-therapeutics/> .